US

With the recent acquisition of Natrol – a leading manufacturer and marketer of branded nutritional products in the United States, Plethico has now expanded its global footprint to the regulated markets of the United States and Europe.

• Natrol distributes products in the US through more than 54,000 retailers, as well as internationally in over 40 countries including the UK, Hong Kong, and China.
• Customers worldwide trust Natrol’s science-based products to enhance their health and well-being.

CIS

• Largely dominated by Russia, Ukraine, Kazakhstan
• An established marketing and distribution network with over 150 people
• Subsidiaries in Russia, Ukraine, Kazakhstan, Kyrgyzstan, Moldova and Azerbaijan
• Representation in Uzbekistan, Armenia, Georgia, Latvia, Turkmenistan and Tajikistan
• Travisil range, herbal food supplements and effervescent range dominate Plethico’s sales in the region supported by strong marketing push and strategy
• More than 200 product approvals in the pharmaceutical, OTC, hospital disposables and herbal products categories
• Rezlov Ltd. – the fully integrated marketing chain in CIS countries has been acquired by Plethico with the following rationale:
  • Expansion of global marketing initiatives to strengthen presence and sales
  • Non-dependence on distributors
  • Protecting recovery
  • Enabling secure and seamless registration of products
  • Allowing company to focus on core competency ie. manufacture of quality products and marketing
  • Providing enhanced realization post acquisition

Europe

• Ongoing efforts for plant approval as per UKMHRA & EU cGMP.
• Focus on branded generics, herbals and Consumer Healthcare products.

Africa

• Operations in East, West, North & South Africa, with scientific offices/subsidiaries in Kenya, Uganda, Conga, Nigeria and Ivory Coast.
• Strong presence in Antibiotics, Anti-Malarials & Anti-TB segments.
• Major supplier to government and semi-government organizations.
• A manufacturing Joint venture in Kenya.

South East Asia

• Operations in Hong Kong, Malaysia, Cambodia, Vietnam, Philippines and Sri Lanka.
• Exports to more than 10 countries.
• Presence in Generics as well as branded formulations.
• A vibrant field force and established brands.

Latin America

• Presence in over 15 countries, covering Central & South America and the Caribbean.
• Focus on OTC, Herbals, NDDS and in-licensing activities.
• Differentiated and marketing efforts are aimed at identifying and establishing niche segments and to create a unique brand identity.

GCC

• Product registrations in Jordan, Bahrain, Oman and Yemen.
• Expansion plans for UAE, Kuwait, Saudi-Arabia and other GCC countries.

Global Markets overview

Worldwide, the neutraceuticals market continues to be driven by growing consumers’ awareness and interest to lead healthy lives and minimize side effects by possibly avoiding use of synthetic drugs. The dietary supplements market, throughout the 1990s demonstrated high growth rates followed by herbal supplement products. Thereafter, non-herbal, sports nutrition and meal supplements showed increasing growth rates. Vitamins and minerals are expected to demonstrate slower growth in worldwide neutraceutical applications, owing to intense pricing competition, overall lack of proprietary compounds and mature product applications. However, Vitamin A and E are anticipated to perform the best amongst bulk vitamins, due to increasing evidence of health benefits and expanding end-user preference for high quality natural formulations. Amongst minerals, calcium and potassium are expected to record highest sales gains based on demonstrated preventive benefits in geriatric and women’s health care.

Outlook

The global neutraceuticals market comprises two principal segments namely dietary supplements and functional foods and is poised to grow at a CAGR of 6.1% in the period 2000 – 2010. Nutraceutical sales are expected to touch US$187.4 billion by 2010 as against an estimated US$155.9 billion for 2007.

The United States represents the largest market world wide for nutraceuticals, with estimated sales of US$50 billion in 2007 and is expected to reach US$59.4 billion by 2010, registering a CAGR of 6% during 2000 – 2010. Europe and Japan are other large markets besides the United States.

Market drivers

• Increasing awareness and better understanding of relationship between ‘diet’ and ‘health’
• Rising interest in consumer-directed healthcare
• Growth in aging population
• Technical developments in the food industry
• Expanding importance of cost control in healthcare delivery – imperative for a growing neutraceutical market
• Media publicity and promotion; and participation in educating audiences – propagation of information outlining the benefits of supplements and health foods
• Scientific studies and clinical trials supporting safety and efficacy claims – intensive R&D especially by leveraging biotechnology to develop food with higher levels of mineral and vitamin content